To investigate the incidence of adverse reactions of recombinant zoster vaccine (RZV) in people≥50 years, and to provide reference for RZV vaccination.

The data of 523 patients who received RZV in the outpatient department of Guizhou Center for Disease Control and Prevention from September 2021 to September 2023 were analyzed.

A total of 523 patients were inoculated with the RZV and the overall incidence of adverse reactions was 50.10%. The incidence of adverse reactions was 63.22% in the 50-59 age group, 40.72% in the 60-69 group, and 26.47% in those aged ≥70 years. Among females and males, the incidence was 44.88% and 61.73%, respectively. The incidence was 61.27% in underweight individuals, 46.59% in those with normal weight, and 30.00% in those who were overweight or obese. Patients with a history of endocrine disease, cardiovascular disease, and shingles showed incidences of 70.83%, 63.72%, and 53.85%, respectively.

The incidence of adverse reactions following RZV vaccination in individuals ≥50 years in Guiyang is relatively low, and most adverse reactions are mild. The incidence rate is influenced by factors such as age, gender, weight, and the presence of underlying diseases. Post-vaccination monitoring and treatment following RZV administration should be tailored to each individual.